Longeveron Licenses Breakthrough Cardiac iPSC Technology to Accelerate Heart Disease Therapies
We’re pleased to share an exciting development from Longeveron Inc., a clinical-stage biotech pioneer in regenerative medicine. The company has just licensed an issued US patent (12,168,028 B2) from the University of Miami for a groundbreaking induced pluripotent stem cell (iPSC) technology tailored to cardiac regeneration. What’s the Innovation? The license covers a method for isolating […]
Can Stem Cells Regenerate the Heart? A Conversation with Dr. Chuck Murray
Can stem cells regenerate damaged heart muscle? Dr. Chuck Murray, a global leader in regenerative medicine, believes they can — and he’s working to make it a reality. As Chair of the Department of Stem Cell Biology and Regenerative Medicine at USC and Director of the Broad Center for Regenerative Medicine, Dr. Murray is driving […]
Advancing Cell Therapy for Heart Failure: BioCardia Announces CardiAMP HF II Trial Begins with First Patient
BioCardia announced the enrollment of the first patient in their Phase 3 CardiAMP HF II clinical trial, which is evaluating their lead cell therapy for heart failure. This trial will assess the safety and effectiveness of the autologous cell therapy, which uses a patient’s own bone marrow cells delivered to the heart to potentially stimulate healing. The study builds on previous trials […]
First in US to Treat Heart Failure with Umbilical Cord Stem Cells
The University of Louisville (UofL) is conducting a groundbreaking Phase II clinical trial called CATO, which represents several significant firsts in heart failure treatment[1][3]: Trial Characteristics The CATO trial is a randomized, double-blind, placebo-controlled study that will enroll 60 patients across three centers: UofL, the University of Miami, and Texas Heart Institute[3]. The study focuses […]
BioCardia Completes Phase III Clinical Trial of Autologous Stem Cell Therapy for Ischemic Heart Failure
BioCardia, Inc., a leader in cellular therapies for cardiovascular diseases, has announced the completion of its pivotal Phase III trial for CardiAMP®, an autologous cell therapy designed to treat ischemic heart failure with reduced ejection fraction (HFrEF). This milestone marks the last patient follow-up in the double-blind, placebo-controlled trial, which aims to assess the safety […]
Breakthroughs in Cardiac Care: 20 Years of Stem Cell Innovation for Heart Health
In a recent event hosted by The Public Lead and moderated by Maya Pomroy, renowned physician-scientists Dr. Deepak Srivastava and Dr. Emerson Perin took the stage to discuss major advancements in stem cell research for cardiac care over the past two decades. This insightful conversation delves into the role of regenerative medicine in treating heart […]
Breakthrough in Heart Health: CardiAMP Cell Therapy’s Phase 3 Trial Launches
BioCardia, a pioneer in cellular therapeutics, has announced the commencement of patient enrollment for its pivotal Phase 3 trial of the CardiAMP Cell Therapy for the treatment of ischemic heart failure with reduced ejection fraction (HFrEF). This marks a significant milestone in advancing innovative treatments for cardiovascular diseases. Key Highlights: Expert Endorsements: Dr. Leslie Miller, […]
Accelerating Heart Disease Research: Allen Institute’s New Disease-Specific Cell Lines
On June 4, 2024, the Allen Institute for Cell Science announced the launch of its first disease-specific cell line collections, marking a significant milestone in genetic heart disease research. This innovative set of tools, specifically designed to advance the study of hypertrophic cardiomyopathy (HCM) and other muscle disorders, represents a groundbreaking step in the quest […]
Revolutionizing Heart Health With The Promising Role of Stem Cell Therapy in Cardiology
Can the key to unlocking the future of heart health lie within our very own cells? Stem cell therapy represents a burgeoning frontier in medical science, especially in the realm of cardiology. This innovative approach could potentially revolutionize the way we treat heart disease, offering hope where conventional treatments may fall short. What are Stem […]
BioCardia Unveils Groundbreaking Results in Phase III CardiAMP Cell Therapy for Heart Failure
BioCardia, Inc., a leader in biotechnological advancements for cardiovascular diseases, recently announced remarkable interim results from its Phase III CardiAMP® Cell Therapy trial for treating advanced chronic heart failure. These findings mark a significant milestone in the pursuit of innovative treatments for heart failure, showcasing the potential of stem cell therapy to revolutionize patient care. […]